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Induction of Donor-Specific 
Tolerance: Is This Achievable?
To the Editor,
The final goal of transplant physicians is the induction of 
donor-specific tolerance (DST), in which the host perma-
nently accepts the graft, but immunity against other anti-
gens is maintained. There have been reports of successful 
induction of DST in rodent models. However, the majority 
of studies have focused primarily on the inhibition of co-
stimulatory signals that regulate the activation of T cells, 
and belatacept, a high-affinity variant of CTLA4-IgG, is 
the only biological drug that has been applied to human 
organ transplantation [1]. Antigen-presenting cells (APCs) 
are activated by the innate immune response, and mature 
APCs are the key regulators of rejection through activation 
of the acquired immune response. Therefore, the control 
of APC maturation is the key step in induction of DST in 
the field of organ transplantation. Previously, we reported 
induction of DST through control of APC maturation [2]. 
However, we were not able to delineate the underlying 
mechanisms, nor apply the methods to other models of 
transplantation. 
Recently, Jung et al. [3] reported a significant contri-
bution where they showed successful induction of DST 
through the control of APC maturation. They developed 
a way to maintain APCs in a semi-arrested state by ad-
ministration of an antibody ligating a particular epitope 
on intercellular adhesion molecule 1 (ICAM-1). Signaling 
through ICAM-1 is important for the activation of APCs. 
They evaluated the effect of semi-arrested APCs on xe-
nogeneic grafts in humanized mice and non-human pri-
mates. Thus, they provided a feasible method that may as-
sist the realization of the DST concept. Further work will 
likely be connected to clinical trials.
However, care should be taken when interpreting these 
results and applying them directly to humans. The study 
was performed not on ‘organs’ but, rather, on a ‘group of 
cells’, because ‘group of cells’ induces a milder immune re-
sponse, as compared to that against an organ. Moreover, a 
thorough method for screening various microorganisms in 
xenogeneic species has not yet been developed. Therefore, 
the safety issue remains to be resolved. Despite these limi-
tations, this study provides new insight and will help over-
come the problem of non-specific immunosuppression. 
Furthermore, this study may facilitate control of immune 
responses more meticulously and safely by providing a 
method of controlling the immune response at the site of 
interest.
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